Metastatic Tumor clinical trials

Explore recruiting metastatic tumor clinical trials.

Recruiting metastatic tumor studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Metastatic Tumor trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

Palbociclib plus fulvestrant in women with hormone receptor positive and human epidermal growth factor receptor type 2 negative locally advanced or metastatic breast cancer previously treated with a CDK4/6 inhibitor in combination with hormonal therapy: a multicenter, phase II trial

Italy

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase 2 Open-Label, Multi-Center Study of BMS-986504 as Monotherapy and in Combination with Other Agents in Participants with Advanced and/or Metastatic Solid Tumors with Homozygous MTAP Deletion

Belgium, Ireland, Germany, Norway, Italy, France +1 more

Therapeutic exploratory (Phase II) EU CTIS Study details

ProspectivE phase 0 pilot study, assessing potential prognostic and theranostic interest of 68Ga-PentiXafor PET-CT In metastatic triple neGative brEast caNCer patiEnts (EXIGENCE)

France

Human Pharmacology (Phase I)- Other EU CTIS Study details

A randomized phase II study of second line treatment with liposomal irinotecan and S1 versus liposomal irinotecan and 5-fluorouracil in patients with metastatic pancreatic cancer who failed on first line gemcitabine-based chemotherapy

Spain, Italy, Netherlands, Austria

Therapeutic exploratory (Phase II) EU CTIS Study details

PET imaging of tumors with strong desmoplastic reaction in pancreas, bile ducts, ventricle and ovaries by a novel tracer, 68Ga-FAPI-46 = Fibroblast Activation Protein Inhibitor

Sweden, Finland

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase I/Ib, open-label, dose finding study to assess the safety, tolerability, pharmacokinetics, and preliminary efficacy of OBT076, a CD205-directed antibody-drug conjugate, in recurrent and/or metastatic CD205-positive solid tumors

France, Spain, Greece, Belgium

Human Pharmacology (Phase I)- Other EU CTIS Study details

Metastatic Tumor trials by city

Metastatic Tumor in Toronto Metastatic Tumor in Vancouver Metastatic Tumor in Montreal Metastatic Tumor in Calgary Metastatic Tumor in Edmonton Metastatic Tumor in Ottawa Metastatic Tumor in Winnipeg Metastatic Tumor in Quebec City Metastatic Tumor in Hamilton Metastatic Tumor in Kitchener Metastatic Tumor in London Metastatic Tumor in Halifax Metastatic Tumor in New York Metastatic Tumor in Los Angeles Metastatic Tumor in Chicago Metastatic Tumor in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease